Regulatory news rarely makes its way to patients in plain language, but it should, because it shapes what clinics can honestly offer. In 2026 the FDA took several notable steps on cell and gene therapies, from new flexibility in manufacturing requirements to a September update of its approved products list. This article translates the fall 2026 regulatory picture into the practical facts you need before considering regenerative treatment.
48
RMAT designations granted by the FDA in 2025, a record
Sept 17, 2026
when the FDA's approved cellular and gene therapy products list was updated to include KRESLADI
0
FDA-approved stem cell products for osteoarthritis or joint pain, unchanged in fall 2026
The most important fact for anyone considering regenerative medicine is unchanged: as of fall 2026, there is still no FDA-approved stem cell product for osteoarthritis, joint pain, or any orthopedic condition, and there are no FDA-approved exosome products for any therapeutic use. The cell-based and PRP treatments offered for joints remain investigational, and an honest clinic says so without hedging.
The direction of travel in 2026 was acceleration. In January, the FDA announced more flexibility on chemistry, manufacturing, and controls requirements for cell and gene therapies. In June, the agency issued draft guidance designed to help developers of cell and gene therapies for rare and life-threatening diseases move faster by reusing established platform data, rather than repeating redundant testing for each new product.
“In June 2026 the FDA issued draft guidance to help accelerate the development of cell and gene therapies, allowing sponsors to reuse established platform data and reduce redundant testing.”
The FDA's Regenerative Medicine Advanced Therapy (RMAT) designation, which fast-tracks promising investigational therapies, reached a record 48 designations in 2025. In July 2026 the agency granted four more, and as of that month three regenerative medicine products had been approved in 2026 with six more under review. These are real milestones, but they are milestones for specific investigational and approved products, mostly in rare and severe diseases, not for the mainstream joint pain market.
On September 17, 2026, the FDA's official list of approved cellular and gene therapy products was updated to include KRESLADI (marnetegragene autotemcel), a gene-corrected autologous stem cell therapy, alongside other approved cellular and gene therapies. Each addition to that list is genuinely good news for the patients those products serve. The practical point for someone considering a knee injection or an infusion in Honolulu is that these approvals are for specific, serious conditions, and none of them authorize stem cell treatments for joint or wellness use.
When marketing mentions the FDA in 2026, it is worth asking exactly which action is being cited. Is it an approval of a specific product for your condition? A trial clearance? A facility registration? A designation meaning the program exists but has not been approved? All of those are different things, and only the first one is an approval. The more specific the claim a clinic can make, and the more precisely they can point to a drug or product name, the more trustworthy it usually is.
A note from the clinic
We track the regulatory picture closely because it shapes what we can honestly offer. At Aloha Stem Cell in Honolulu, our cell-based and PRP treatments are autologous and investigational for most conditions, and we will always tell you exactly where the evidence stands, including what is approved and what is not. Call (808) 593-2525 or book a consultation.
Our team is happy to listen to your story, answer your questions, and help you decide whether a consultation makes sense. There is no pressure and no obligation.
Keep reading
The FDA now lists Regenecyte, a cord blood stem cell product, among approved cellular therapies. It is a real milestone for blood stem cell transplant patients, and it is not a treatment for joint pain. Here is what the approval is, what it is not, and why it matters when you read stem cell news.
In September 2026 the FDA granted Fast Track status to an experimental cell therapy for ALS, and in August researchers presented new Phase 1/2 data on a stem cell therapy for Parkinson's. Both are real advances and both remain investigational. Here is the honest read.
A stem cell-derived islet therapy restored insulin production in early trials, with 10 of 12 patients insulin-independent at one year. Here is what the 2025-2026 results show, what the FDA has and has not done, and what it means for people with diabetes.
Book a consultation
Pick a time that works for you and our team will confirm your consultation. Questions first? Call us anytime at (808) 593-2525.